On January 6, Insmed’s chief financial officer, Sara Bonstein, divested 1,517 shares of company stock in a single transaction valued at approximately $262,942. This sale was formally disclosed in an SEC filing and marks the beginning of a three-day period during which Bonstein sold a cumulative 4,642 shares for proceeds totaling roughly $809,732. These dispositions reflect active portfolio management by the CFO and signal a 1.78% reduction in her stake following the initial sale.

Following the January 6 trade, Bonstein’s direct holdings declined from 85,148 to 83,631 shares, with a pro forma value of $14.5 million. Over the January 7–8 window, additional sales reduced her position further to 80,506 shares, representing a total ownership decrease of approximately 5.46% since the start of the week. While still a substantial equity stake, the concentrated nature of these insider sales has caught investor attention and may influence perceptions of executive confidence in the near-term outlook.

Bonstein was joined by other senior Insmed executives in selling shares during the same January 6–8 period, with aggregate insider transactions exceeding $15 million. This wave of disposals coincides with the opening of an investor investigation by Pomerantz LLP into the company, introducing potential reputational risks. Investors are weighing these developments alongside upcoming clinical data milestones—ENCORE Phase 3 topline results expected March/April 2026 and CEDAR Phase 2b readouts in Q2 2026—as they assess both corporate governance trends and near-term volatility drivers.